The U.S. Food and Drug Administration (FDA) has approved Baqsimi (glucagon) nasal powder 3mg for the treatment of severe hypoglycemia in people with diabetes ages four years and above, as announced by Eli Lilly and Company. Baqsimi is the first and only nasally administered glucagon, and it was designed with severe hypoglycemia rescue in mind. It is compact, portable and ready to use (no reconstitution required) in a single, fixed, 3mg dose. In a trial with adult patients, Baqsimi had comparable efficacy to injectable glucagon. Common cold with nasal congestion did not impair absorption of the product. It will be a while before the product will be widely available in the US or globally.